NVP-AEW541

For research use only.

Catalog No.S1034 Synonyms: AEW541

55 publications

NVP-AEW541 Chemical Structure

CAS No. 475489-16-8

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

Selleck's NVP-AEW541 has been cited by 55 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
Targets
Insulin Receptor [1]
(Cell-free assay)
IGF-1R [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
Tek [1]
(Cell-free assay)
FLT1 [1]
(Cell-free assay)
0.14 μM 0.15 μM 0.42 μM 0.53 μM 0.6 μM
In vitro

NVP-AEW541 also inhibits InsR, Tek, Flt1 and Flt3 with IC50 of 140 nM, 530 nM, 600 nM and 420 nM in purified kinases/recombinant kinase domains assay. NVP-AEW541 is more selective and shows 27-fold more potent than InsR at the cellular level. NVP-AEW541 suppresses the IGF-I-mediated survival, soft agar and proliferation of MCF-7 cells with IC50 of 0.162 μM, 0.105 μM and 1.64 μM, respectively. NVP-AEW541 also reduces the level of phospho-IGF-1R and phospho-PKB in NWT-21 cells. [1] NVP-AEW541 shows growth inhibitory effect on TC-71 musculoskeletal sarcoma cells in low-serum medium as well as in 10% FBS–containing medium. NVP-AEW541 inhibits cell cycle progression and induces specific G1 arrest in sarcoma cell lines (TC-71, SK-N-MC, SaoS-2, RD/18 and RH4). [2] NVP-AEW541 could inhibit the growth of human neuroblastoma cells with IC50 of 0.4-6.8 μM. An increase in the hypodiploid fraction and the depletion of the S and G2-M compartments could be detected in these cell lines. NVP-AEW541-driven inhibition of IGF-1R causes a reduction of phosphorylation of Akt, but not of Erk1 and Erk2 in neuroblastoma cells. [3] NVP-AEW541 inhibits glioma cell growth and disrupts the autocrine loop initiated by HIF1α stabilization. [4] A recent study shows that NVP-AEW541 suppresses the proliferation and viability of PC3, DU145, and 22Rv1 prostate cancer cells, without necessarity of associated cell death. NVP-AEW541 decreases phospho-Akt levels in 22Rv1 and DU415 cells but not PC3 cells, without affecting total Akt levels, which shows that PTEN status could determine the effectiveness of NVP-AEW541 with essential Akt. NVP-AEW541-induced radiosensization is dependent on Akt activation status. NVP-AEW541 could increase the H2AX phosphorylation (a measure of DSBs) in PC3, DU145, and 22Rv1 cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NWT-21 MXzLbY5ie2ViYYPzZZk> M17xXp4yOOLCit88US=> MkH0SG1UVw>? MUXpcohq[mm2czDJS2YuUVJid3n0bEBKSzVyIH;mJFAvODh4INMxJFAvODJ6IN88US=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB3MEmxOUc,OTVyNUC5NVU9N2F-
A14 NEPPeYxMcW6jc3WgZZN{[Xl? M3;X[Z4yOOLCit88US=> NWPB[nRQTE2VTx?= NYHmUXdicW6qaXLpeJMhUW6|UjD3bZRpKEmFNUCgc4YhOi5|INMxJFAvOTZ|IN88US=> NW\ScYwxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWwOVA6OTVpPkG1NFUxQTF3PD;hQi=>
A431  NGG1TlBMcW6jc3WgZZN{[Xl? MmnyglEx6oDMzszN NFjsNVdFVVOR NUnKU2ZvcW6qaXLpeJMhUEWUMTD3bZRpKEmFNUCgc4YhRjFyIN88US=> NEnu[pY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUC1NFkyPSd-MUWwOVA6OTV:L3G+
A31  MmTVT4lv[XOnIHHzd4F6 MlHDglEx6oDMzszN M4TB[WROW09? NXXtUJZvcW6qaXLpeJMhWESJRmKge4l1cCCLQ{WwJI9nKD5zMDFOwG0> NEG4XYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUC1NFkyPSd-MUWwOVA6OTV:L3G+
GIST882 NFi1cXhMcW6jc3WgZZN{[Xl? MYf+NVDjiIsQvF2= NH\qXo1FVVOR NVjIeGhVcW6qaXLpeJMh[y2NaYSge4l1cCCLQ{WwJI9nKD53IN88US=> M1nPR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MEWwPVE2Lz5zNUC1NFkyPTxxYU6=
32D-Bcr-Abl M2LTVmtqdmG|ZTDhd5NigQ>? NIqwWJh,OTEkgJtOwG0> M32weWROW09? M2niTYlvcGmkaYTzJGJkei2DYnygdFIyOCC5aYToJGlEPTBib3[gQlExKM7:TR?= Ml;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVyNUC5NVUoRjF3MEWwPVE2RC:jPh?=
MCF-7  Mnn6R5l1d3irY3n0fUBie3OjeR?= NX3sNplKTE2VTx?= NF21cWxKSzVyPUGuOlQh|ryP MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB3MEmxOUc,OTVyNUC5NVU9N2F-
NWT-21 M{jYSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MkDVSG1UVw>? M{PkO2lEPTB;MD6xOlMh|ryP MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB3MEmxOUc,OTVyNUC5NVU9N2F-
TC-71 MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NFTXUlh,OSEQvF2= NXruNo94TE2VTx?= NF3QWY5qdmirYnn0d{BqdnO3bHnuMYxqc2ViZ4Lve5RpKG[jY4Tvdk1K6oDVbXXkbYF1\WRiZ4Lve5Rp NUK1d4d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4Olc{QDZpPkG1PFY4Ozh4PD;hQi=>
TC-71 M1X3c2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NGDHUXl,P+LCit88US=> NX;PdlNzTE2VTx?= NEXkZ3RKSzVyPECuOUDPxE1? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh4N{O4Okc,OTV6NkezPFY9N2F-
Saos-2 NULQT|UxT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MXT+O-KBks7:TR?= MmDrSG1UVw>? MVHJR|UxRDNizszN NX\qSXBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4Olc{QDZpPkG1PFY4Ozh4PD;hQi=>
U-2OS NEOwV4NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MV7+O-KBks7:TR?= NVTEfWJlTE2VTx?= MXTJR|UxRDBwNTFOwG0> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh4N{O4Okc,OTV6NkezPFY9N2F-
SK-ES-1 NYT4[5VMT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFrjOGh,P+LCit88US=> MkOySG1UVw>? Mkf5TWM2ODxyLkWg{txO NHf5WnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUi2O|M5Pid-MUW4Olc{QDZ:L3G+
SK-N-MC NGr5[JZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWj2d4Z[hjgkgJtOwG0> MnXLSG1UVw>? NFzIZ5ZKSzVyPECuOUDPxE1? M1LFd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OE[3N|g3Lz5zNUi2O|M5PjxxYU6=
RD-ES M1vnNWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEDXe|B,P+LCit88US=> MYXEUXNQ M1jDcGlEPTB:MD61JO69VQ>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh4N{O4Okc,OTV6NkezPFY9N2F-
SJ-Rh 30 M3rv[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2n0fZ446oDMzszN NIjycnNFVVOR MYXJR|UxRDBwNTFOwG0> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh4N{O4Okc,OTV6NkezPFY9N2F-
SJ-Rh 4 MlWxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MlXCglfjiIsQvF2= M2nRfWROW09? M1OybWlEPTB:MD61JO69VQ>? M{H1d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OE[3N|g3Lz5zNUi2O|M5PjxxYU6=
6647 MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MnftglfjiIsQvF2= M1\GXmROW09? NFm0dmxKSzVyPECuOUDPxE1? NGrZ[4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUi2O|M5Pid-MUW4Olc{QDZ:L3G+
SARG NGDBenhIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWTFRVlGhjgkgJtOwG0> Mn\ISG1UVw>? MknlTWM2ODx|IN88US=> M37Td|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OE[3N|g3Lz5zNUi2O|M5PjxxYU6=
MOS M1zlb2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MojOglfjiIsQvF2= M17mS2ROW09? NUHTV|RnUUN3MEy0JO69VQ>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh4N{O4Okc,OTV6NkezPFY9N2F-
IOR/OS7 MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXr+O-KBks7:TR?= Mom2SG1UVw>? NEWyVppKSzVyPEGg{txO M2\rdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OE[3N|g3Lz5zNUi2O|M5PjxxYU6=
IOR/OS9 Mo\LS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MV3+O-KBks7:TR?= NXLsRpltTE2VTx?= MonQTWM2ODx4IN88US=> NIjDNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUi2O|M5Pid-MUW4Olc{QDZ:L3G+
IOR/OS10 NIC5fmdIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NWP4XJlthjgkgJtOwG0> M3L5RWROW09? M{i0c2lEPTB:NTFOwG0> M{jRVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OE[3N|g3Lz5zNUi2O|M5PjxxYU6=
IOR/OS14 NFvXco1Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NIrMfFV,P+LCit88US=> MnX3SG1UVw>? NYj0eGdbUUN3MEy0JO69VQ>? Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6NkezPFYoRjF3OE[3N|g3RC:jPh?=
LAP35 M1TBR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M2X0eJ446oDMzszN NVzLeohDTE2VTx?= NGHDOZNKSzVyPECuOUDPxE1? NUTWeWFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4Olc{QDZpPkG1PFY4Ozh4PD;hQi=>
IOR/BRZ M4HyRmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NEK2XWZ,P+LCit88US=> M3XCXWROW09? NH\ScI9KSzVyPECuOUDPxE1? MoKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6NkezPFYoRjF3OE[3N|g3RC:jPh?=
IOR/CAR NX35[XdiT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NIXQdHF,P+LCit88US=> Mn3ZSG1UVw>? NULxW|lQUUN3MEyxJO69VQ>? NIjtV2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUi2O|M5Pid-MUW4Olc{QDZ:L3G+
IOR/NGR NIn3dZVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M{DKeJ446oDMzszN M4fGSGROW09? MV\JR|UxRDBwNTFOwG0> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh4N{O4Okc,OTV6NkezPFY9N2F-
IOR/RCH NIXQ[WlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVjPW5M4hjgkgJtOwG0> MV3EUXNQ NFfKNItKSzVyPECuOUDPxE1? MnroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6NkezPFYoRjF3OE[3N|g3RC:jPh?=
RMZ-RC2 NVLlT2duT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NV3TbYlVhjgkgJtOwG0> NYTZOlBpTE2VTx?= NEC0WGlKSzVyPECuOUDPxE1? NFPuWYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUi2O|M5Pid-MUW4Olc{QDZ:L3G+
CCA MkPrS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYDqU3ZshjgkgJtOwG0> MXzEUXNQ MX7JR|UxRDJizszN MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh4N{O4Okc,OTV6NkezPFY9N2F-
RD/18 MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NHPnRWZ,P+LCit88US=> NGfLU4RFVVOR NULXUWx5UUN3MEy0JO69VQ>? NF\peJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUi2O|M5Pid-MUW4Olc{QDZ:L3G+
OVCAR-3 NUC3WlB3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NInucXp,OTYkgJtOwG0> M{eyW2ROW09? NYD3SY5HcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9v M1\vNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4M{CwPFIxLz5zNkOwNFgzODxxYU6=
OVCAR-4 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M33mbp4yPeLCit88US=> MYDEUXNQ Mk\WbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NYK3c|lrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[zNFA5OjBpPkG2N|AxQDJyPD;hQi=>
OVCAR-3 M2m5bmFxd3C2b4Ppd{Bie3OjeR?= MnXvglE26oDMzszN NHTNZ3lFVVOR NV:1c5cycW6mdXPld{BieG:ydH;zbZM> NVnoeJo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[zNFA5OjBpPkG2N|AxQDJyPD;hQi=>
OVCAR-4 MXHBdI9xfG:|aYOgZZN{[Xl? MknvglE26oDMzszN M3fqeGROW09? MoW0bY5lfWOnczDhdI9xfG:|aYO= M1PWT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4M{CwPFIxLz5zNkOwNFgzODxxYU6=
OVCAR-3 M3X4RmZ2dmO2aX;uJIF{e2G7 M4TkcJ4yPeLCit88US=> M2HQXGROW09? NWfkXIxlTGWlcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= MkjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ|MEC4NlAoRjF4M{CwPFIxRC:jPh?=
Huh-7 NGnUNWlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NYjyXpNphjFy4pEK{txO NUDJZpdCTE2VTx?= NVLnU|lPUUN3ME2xMlQh|ryP NXG3PJVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[1N|A4OzRpPkG2OVMxPzN2PD;hQi=>
Hep-G2 NUXRS20zT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2nQNZ4yOOLCit88US=> M2S4[GROW09? NGW5RXdKSzVyPUGuPEDPxE1? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjV|MEezOEc,OTZ3M{C3N|Q9N2F-
Hep-3B MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MVP+NVDjiIsQvF2= NGT2PJFFVVOR MXTJR|UxRTFwOTFOwG0> M4TINFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NUOwO|M1Lz5zNkWzNFc{PDxxYU6=
SK-Hep-1 NUn4TGt7T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1y2PZ4yOOLCit88US=> MVvEUXNQ NU\udlQ2UUN3ME22Mlkh|ryP Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ3M{C3N|QoRjF4NUOwO|M1RC:jPh?=
Huh-7 NVvFO5d7TnWwY4Tpc44h[XO|YYm= NY\RRZZLhjFy4pEK{txO M4H5UGROW09? NV7ZSHNnUW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NEDSfZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkWzNFc{PCd-MU[1N|A4OzR:L3G+
Hep-G2 NYDEUXVGTnWwY4Tpc44h[XO|YYm= NIm2[ol,OTEkgJtOwG0> NUHBWW5qTE2VTx?= MYLJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 M{L0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NUOwO|M1Lz5zNkWzNFc{PDxxYU6=
SK-Hep-1 NX\0Vlg2TnWwY4Tpc44h[XO|YYm= MXL+NVDjiIsQvF2= M1XRb2ROW09? MmHlTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjV|MEezOEc,OTZ3M{C3N|Q9N2F-
BON MYfLbY5ie2ViYYPzZZk> M{TKR543KM7:TR?= NVuzW5JVTE2VTx?= NU\PZXo5cW6mdXPld{Bl\XCqb4PwbI9zgWyjdHnvckBw\iCLR1[tNXI> NIfhZpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNk[wNVI5PCd-MU[2NFEzQDR:L3G+
BON Ml;JS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? Ml7YglEx6oDMzszN NVjHS41PTE2VTx?= MX3JR|UxRTZwNjFOwG0> NI\WO4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNk[wNVI5PCd-MU[2NFEzQDR:L3G+
CM MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYf+OgKBks7:TR?= MWrEUXNQ MnrKTWM2OD1|LkOg{txO NYPLW4twRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2NFEzQDRpPkG2OlAyOjh2PD;hQi=>
BON NG\ybHhHfW6ldHnvckBie3OjeR?= MVf+O{426oDMzszN M3PCfmROW09? NHTFeI9qdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 MlzGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4MEGyPFQoRjF4NkCxNlg1RC:jPh?=
CM MkDrSpVv[3Srb36gZZN{[Xl? MUL+OgKBks7:TR?= MojUSG1UVw>? MULpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2 Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ4MEGyPFQoRjF4NkCxNlg1RC:jPh?=
BON NEfvOXJCeG:ydH;zbZMh[XO|YYm= NX\VSllHhjdwNfMAju69VQ>? NIXWNplFVVOR MmiybY5lfWOnczDBdI9xfG:|aYO= NXj0SWdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[2NFEzQDRpPkG2OlAyOjh2PD;hQi=>
CM M2XSR2Fxd3C2b4Ppd{Bie3OjeR?= NXLGUGZihjYkgJtOwG0> MojvSG1UVw>? NXTDZoFTcW6mdXPld{BCeG:ydH;zbZM> M2X5b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NkCxNlg1Lz5zNk[wNVI5PDxxYU6=
HT-29 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVnZbJM3hjFy4pEK{txO MlewSG1UVw>? MVrJR|UxRTFwNzFOwG0> M3Pr[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MEC3NFE2Lz5zN{CwO|AyPTxxYU6=
HCT-116 MlvSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NUHzcotPhjFy4pEK{txO Mk\RSG1UVw>? MkezTWM2OD1{LkWg{txO MmnWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyMEewNVUoRjF5MEC3NFE2RC:jPh?=
primary colorectal cancer cells M4XBcGZ2dmO2aX;uJIF{e2G7 M2LUcp426oDMzszN MV\EUXNQ MVvhcJRmenNidHjlJI1wenCqb3zv[5khd2ZidHjlJJJmdWGrbnnu[{Bk\Wyucx?= MmHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyMEewNVUoRjF5MEC3NFE2RC:jPh?=
HTLA-230 MlPoSpVv[3Srb36gZZN{[Xl? MUL+PEDPxE1? NHfTZY5FVVOR NV3JZ3RrcW6qaXLpeJMhUUeILVnJMY1m\GmjdHXkJJN1cW23bHH0bY9vKG:oIFnHSk1KWiCjbnSgRYt1 MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{MUi5PEc,OTdzMkG4PVg9N2F-
KCNR MkO3SpVv[3Srb36gZZN{[Xl? NVzX[opqhjhizszN NYThSnlzTE2VTx?= MXrpcohq[mm2czDJS2YuUUlvbXXkbYF1\WRic4TpcZVt[XSrb36gc4YhUUeILVnSJIFv\CCDa4S= NHXLS5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyNVg6QCd-MUexNlE5QTh:L3G+
SK-N-BE2c MojHSpVv[3Srb36gZZN{[Xl? NWHxWog5hjhizszN NE\NUo1FVVOR NWK3NY92cW6qaXLpeJMhUUeILVnJMY1m\GmjdHXkJJN1cW23bHH0bY9vKG:oIFnHSk1KWiCjbnSgRYt1 MlGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzMkG4PVgoRjF5MUKxPFk5RC:jPh?=
SK-N-BE MkTSSpVv[3Srb36gZZN{[Xl? NI\TR2R,QCEQvF2= M4jneGROW09? MoC2bY5pcWKrdIOgTWdHNUmLLX3l[IlifGWmIIP0bY12dGG2aX;uJI9nKEmJRj3JVkBidmRiQXv0 M3jSTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUKxPFk5Lz5zN{GyNVg6QDxxYU6=
LAN-5 M{fuRmZ2dmO2aX;uJIF{e2G7 MkTIglgh|ryP M{nKPGROW09? MUTpcohq[mm2czDJS2YuUUlvbXXkbYF1\WRic4TpcZVt[XSrb36gc4YhUUeILVnSJIFv\CCDa4S= Ml7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzMkG4PVgoRjF5MUKxPFk5RC:jPh?=
GI-CA-N NF\BR45HfW6ldHnvckBie3OjeR?= NFvi[VJ,QCEQvF2= Mn3BSG1UVw>? MYDpcohq[mm2czDJS2YuUUlvbXXkbYF1\WRic4TpcZVt[XSrb36gc4YhUUeILVnSJIFv\CCDa4S= NHrmToI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyNVg6QCd-MUexNlE5QTh:L3G+
SH-EP MVfGeY5kfGmxbjDhd5NigQ>? NUXWSJlJhjhizszN M3jDWGROW09? MXPpcohq[mm2czDJS2YuUUlvbXXkbYF1\WRic4TpcZVt[XSrb36gc4YhUUeILVnSJIFv\CCDa4S= NWfrWGhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlE5QThpPkG3NVIyQDl6PD;hQi=>
SK-N-AS NIexSnJHfW6ldHnvckBie3OjeR?= NX7iOJhthjhizszN MUPEUXNQ NXzjSYw5cW6qaXLpeJMhUUeILVnJMY1m\GmjdHXkJJN1cW23bHH0bY9vKG:oIFnHSk1KWiCjbnSgRYt1 MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{MUi5PEc,OTdzMkG4PVg9N2F-
RN-GA NGDZOXhHfW6ldHnvckBie3OjeR?= MmPtglgh|ryP M{fYSmROW09? MnTQbY5pcWKrdIOgTWdHNUmLLX3l[IlifGWmIIP0bY12dGG2aX;uJI9nKEmJRj3JVkBidmRiQXv0 M120UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUKxPFk5Lz5zN{GyNVg6QDxxYU6=
SY-5Y(N) MmPMSpVv[3Srb36gZZN{[Xl? NGTPUIh,QCEQvF2= M3qwUWROW09? M1jKVolvcGmkaYTzJGlITi2LST3t[YRq[XSnZDDzeIlufWyjdHnvckBw\iCLR1[tTXIh[W6mIFHreC=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{MUi5PEc,OTdzMkG4PVg9N2F-
GI-CA-N NH\QZpFIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M4i4ep45KM7:TR?= M4rXc2ROW09? MU\JR|UxRSB4Lkig{txO NEK5WGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyNVg6QCd-MUexNlE5QTh:L3G+
SH-EP MkLFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NYrJd4FihjhizszN NVfZO5hXTE2VTx?= M3rUOWlEPTB;IEOg{txO M3fCeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUKxPFk5Lz5zN{GyNVg6QDxxYU6=
HTLA-230 NGnBbXJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MoTmglgh|ryP NHO1Z4ZFVVOR NFrrZ5JKSzVyPTCwMlUh|ryP MlfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzMkG4PVgoRjF5MUKxPFk5RC:jPh?=
SK-N-BE2c M2\ZR2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M4q4cJ45KM7:TR?= NUjvfGYyTE2VTx?= MWTJR|UxRSBzLkGg{txO NXTRXJJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlE5QThpPkG3NVIyQDl6PD;hQi=>
SK-N-BE2 M3rLWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NIXJNlV,QCEQvF2= NHfaPZBFVVOR NWrUbJdFUUN3ME2gN{DPxE1? MnfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzMkG4PVgoRjF5MUKxPFk5RC:jPh?=
SY-5Y (N) MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NGCwWGN,QCEQvF2= MmTKSG1UVw>? MoDhTWM2OD1iMj60JO69VQ>? MkD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzMkG4PVgoRjF5MUKxPFk5RC:jPh?=
LAN-5 MlPaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmLrglgh|ryP NV\nZWVmTE2VTx?= NF;vXXlKSzVyPTCwMlQh|ryP NVzUbGVbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlE5QThpPkG3NVIyQDl6PD;hQi=>
KCNR MnPKS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NGfIWFF,QCEQvF2= MnnUSG1UVw>? NXjVWGkxUUN3ME2gNE41KM7:TR?= MonUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzMkG4PVgoRjF5MUKxPFk5RC:jPh?=
RN-GA MnXHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MUT+PEDPxE1? MVrEUXNQ NV3reo51UUN3ME2gNU4{KM7:TR?= MmjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzMkG4PVgoRjF5MUKxPFk5RC:jPh?=
SK-N-AS MV;Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYX+PEDPxE1? M13yeGROW09? NXzYcGplcW6mdXPld{BieG:ydH;zbZM> NUfXbHpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlE5QThpPkG3NVIyQDl6PD;hQi=>
KCNR M2jy[2Fxd3C2b4Ppd{Bie3OjeR?= MXf+PEDPxE1? NWfsOXF3TE2VTx?= MV3pcoR2[2W|IHHwc5B1d3Orcx?= M3rwVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUKxPFk5Lz5zN{GyNVg6QDxxYU6=
GI-CA-N NV\PUYJFSXCxcITvd4l{KGG|c3H5 MWf+PEDPxE1? MXHEUXNQ MUPpcoR2[2W|IHHwc5B1d3Orcx?= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{MUi5PEc,OTdzMkG4PVg9N2F-
HTLA-230 MX3BdI9xfG:|aYOgZZN{[Xl? MUj+PEDPxE1? Mn\USG1UVw>? NUjWS3ZkcW6mdXPld{BieG:ydH;zbZM> NH\nNJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyNVg6QCd-MUexNlE5QTh:L3G+
SK-N-BE2c M1H4N2Fxd3C2b4Ppd{Bie3OjeR?= M2DaOp45KM7:TR?= MUXEUXNQ NWPrSJZjcW6mdXPld{BieG:ydH;zbZM> NXPWW4JKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexNlE5QThpPkG3NVIyQDl6PD;hQi=>
SY-5Y (N) M1\NXGFxd3C2b4Ppd{Bie3OjeR?= NF7Jbm9,QCEQvF2= MonTSG1UVw>? Mmf5bY5lfWOnczDhdI9xfG:|aYO= M16yb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUKxPFk5Lz5zN{GyNVg6QDxxYU6=
HL60AR MmDlSpVv[3Srb36gZZN{[Xl? Mn\2NVYxKG6P NGLKSGhmdmijbnPld{B1cGVibHX2[Yx{KG:oIICyO2tqeDF? M4jrfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[xNlI2Lz5zN{O2NVIzPTxxYU6=
HL60AR MkTORZBweHSxc3nzJIF{e2G7 MXn+NlAxKG6P NV:1WWt6cW6mdXPld{BieG:ydH;zbZM> NWrNeWs{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezOlEzOjVpPkG3N|YyOjJ3PD;hQi=>
HPAF-II M{DOZ2tqdmG|ZTDhd5NigQ>? M3\BfJ4yKM7:TR?= NIiwb5JFVVOR MYnpcohq[mm2czDJS2YuUS2vZXTpZZRm\CC|aXfuZYxtcW6p M4fxcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NES1OVIxLz5zOES0OVUzODxxYU6=
HPAF-II MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M1TNR54zKM7:TR?= M2TZdmROW09? M3jzbolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvci=> NWPye3ViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0OFU2OjBpPkG4OFQ2PTJyPD;hQi=>
HPAF-II NGrNRlhHfW6ldHnvckBie3OjeR?= MoHFglIh|ryP MkGwSG1UVw>? MVrpcohq[mm2czDiZZNidCCjbnSgTWdHNUlvbXXkbYF1\WRicHHuZ5Jm[XSrYzDjZY5k\XJiY3XscEBucWe{YYTpc44> MmLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NEW1NlAoRjF6NES1OVIxRC:jPh?=
TFK-1 M3HjO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 Mmn2glI2OCCwTR?= M2GxbWROW09? M3jZWGlEPTB;MD6yOkDPxE1? NH\VcIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC2Olc{PCd-MkCwOlY4OzR:L3G+
EGI-1 NG\me5pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NHXFcGx,OjVyIH7N NGrHUGZFVVOR M{eyWmlEPTB;MD6yPEDPxE1? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4NkezOEc,OjByNk[3N|Q9N2F-
CC-LP-1 Mk\CS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NWew[VVFhjJ3MDDuUS=> MVLEUXNQ MoXUTWM2OD1yLkG1JO69VQ>? M3;GS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyME[2O|M1Lz5{MEC2Olc{PDxxYU6=
CC-SW-1 M3ft[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmHrglI2OCCwTR?= NH;IbIRFVVOR MUTJR|UxRTBwNUSg{txO NIrzR249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC2Olc{PCd-MkCwOlY4OzR:L3G+
Sk-ChA-1 MoLSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVXkXWlGhjJ3MDDuUS=> MoPMSG1UVw>? M2W5emlEPTB;MD6yJO69VQ>? NF;4ZmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEC2Olc{PCd-MkCwOlY4OzR:L3G+
Mz-ChA-1 NV\2R3hKT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3LoVJ4zPTBibl2= NYjseIZiTE2VTx?= NYrN[Gp{UUN3ME2xMlM6KM7:TR?= MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjByNk[3N|QoRjJyME[2O|M1RC:jPh?=
Mz-ChA-2 NUiyWoRFT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M2rCV54zPTBibl2= M2jTN2ROW09? NIP1dplKSzVyPUCuO|Mh|ryP MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB4NkezOEc,OjByNk[3N|Q9N2F-
ECC-1 NF76UYpMcW6jc3WgZZN{[Xl? NWWxTGRLhjFyIN88US=> MnjDSG1UVw>? NX\wRnFDcW6qaXLpeJMhUUeILVnSJIFkfGm4YYTpc44h[nliOUil M3;R[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkm1N|M2Lz5{MUK5OVM{PTxxYU6=
Ishikawa NV\HdGlQU2mwYYPlJIF{e2G7 NH\rR4J,OTBizszN M1rlRWROW09? MUTpcohq[mm2czDJS2YuUVJiYXP0bZZifGmxbjDifUA6OyV? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ7NUOzOUc,OjF{OUWzN|U9N2F-
USPC-1 Mkn0T4lv[XOnIHHzd4F6 Mn;lglExKM7:TR?= NIPNUW5FVVOR NGjJcJpqdmirYnn0d{BKT0ZvSWKgZYN1cX[jdHnvckBjgSBzMECl Mme1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUWzN|UoRjJzMkm1N|M2RC:jPh?=
USPC-2 MljoT4lv[XOnIHHzd4F6 MUf+NVAh|ryP NGj2PZJFVVOR M{nTVolvcGmkaYTzJGlITi2LUjDhZ5RqfmG2aX;uJIJ6KDl4JR?= NYPZd3N5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVU{OzVpPkKxNlk2OzN3PD;hQi=>
ECC-1 NXfSeFlNT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYfRcVR4hjFyIN88US=> MYTEUXNQ NELpd5Fl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v NFzR[Y09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUK5OVM{PSd-MkGyPVU{OzV:L3G+
Ishikawa NUjmS|dET3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NULnO5h2hjFyIN88US=> NXi3UWFSTE2VTx?= MlfT[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> NYLyTop7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyPVU{OzVpPkKxNlk2OzN3PD;hQi=>
USPC-1 NYqye21ST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NYfxWGxNhjFyIN88US=> NWnyOHJGTE2VTx?= MnnG[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> Ml3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{OUWzN|UoRjJzMkm1N|M2RC:jPh?=
USPC-2 MmjWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M4HJVp4yOCEQvF2= M1HyeGROW09? M4\ZcoRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44> M3PTfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkm1N|M2Lz5{MUK5OVM{PTxxYU6=
Ba/F3 NUTHeWpZTnWwY4Tpc44h[XO|YYm= MlniTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDJS2YuOSC{ZXPldJRweiBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJGJiN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD1yLkCy{txO NEHjeHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm1NVc2Oyd-Mk[5OVE4PTN:L3G+
HEK293 NVLnOIx7TnWwY4Tpc44h[XO|YYm= M3juZVYxKG2rboO= NYHYUWZQUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBKT0ZvMTDy[YNmeHSxcjCoeY5sdm:5bjDvdolocW5rIHH1eI9xcG:|cHjvdplt[XSrb36geJJidnOoZXP0[YQhcW5iSFXLNlk{KGOnbHzzJJBz\XS{ZXH0[YQh\m:{IE[wJI1qdnNiZn;scI94\WRiYomgTWdHNTFic4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDxeYFvfGm2YYTpeoUhX2W|dHXyckBjdG:2IHHuZYx6e2m|LDDJR|UxRTBwME[1{txO NFXkcZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm1NVc2Oyd-Mk[5OVE4PTN:L3G+
HEK293 MmnJSpVv[3Srb36gZZN{[Xl? MUPEbZNxdGGlZX3lcpQhd2ZiW{PIYU1ld2[ndHnsbYRmKG[{b32gbJVu[W5iRWLHJINp[W6wZXyg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczygTWM2OD1yLkGz{txO NYnWSlU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OVE4PTNpPkK2PVUyPzV|PD;hQi=>
Ba/F3 M130RmZ2dmO2aX;uJIF{e2G7 MVvJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHnud5VtcW5icnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSC2cnHud4Zm[3SnZDDpckBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;MD6yOFTPxE1? NHvwOZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm1NVc2Oyd-Mk[5OVE4PTN:L3G+
HEK293 NVrOdVR2TnWwY4Tpc44h[XO|YYm= NWPxTol4PjBibXnudy=> MUDJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHnud5VtcW5icnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSCjdYTvdIhwe3Cqb4L5cIF1cW:wIITyZY5{\mWldHXkJIlvKEiHS{K5N{Bk\WyuczDwdoV1emWjdHXkJIZweiB4MDDtbY5{KG[xbHzve4VlKGK7IFnHSk0yKHO2aX31cIF1cW:wIH3lZZN2emWmIHHmeIVzKDFyIH3pcpMh[nlicYXhcpRqfGG2aY\lJHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0xNjh7Mt88US=> NX\TOHEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OVE4PTNpPkK2PVUyPzV|PD;hQi=>
TC32 M1rWXpFJXFNiYYPzZZk> M2jQeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| M2i5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MmjSdWhVWyCjc4PhfS=> MlG4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= NYHMcmRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 MmjudWhVWyCjc4PhfS=> MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| M3TxXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NYT5[4dseUiWUzDhd5NigQ>? NXTRO3hTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NVHCe2FCeUiWUzDhd5NigQ>? NH;1SYlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz M4TPPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NHXhc2dyUFSVIHHzd4F6 NF7EcmNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? NWjVflRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NHPK[FJyUFSVIHHzd4F6 MlXtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NHjN[Ig9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

In vivo NVP-AEW541 (50 mg/kg, p.o.) results in abrogation of basal and IGF-I-induced receptor, and PKB and MAPK phosphorylation, with T/C value of 14% in the NWT-21 tumor xenograft. [1] NVP-AEW541 (50 mg/kg) causes tumor shrinkage in both HTLA-230 and SK-N-BE2c xenografts, without signs of systemic toxicity. NVP-AEW541 could inhibit tumor invasion both in Matrigel-coated chambers and in HTLA-230 xenografts. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase assays:

NVP-AEW541 is dissolved in DMSO (10 mM) and stored at -20 °C. Dilutions are freshly made in DMSO/water 1:1. The final concentration of DMSO in the enzyme assays is <0.5 %. The protein kinase assays are carried out in 96-well plates at RT and terminated by the addition of 20 μL of 125 mM EDTA. Subsequently, 30 μL (c-Abl, c-Src, IGF-1R) of the reaction mixture are transferred onto Immobilon-PVDF presoaked for 5 min with methanol, rinsed with water, then soaked for 5 min with 0.5 % H3PO4 and mounted on vacuum manifold. After spotting all samples, vacuum is connected and each well rinsed with 200 μL 0.5 % H3PO4. Membranes are removed and washed 4× on a shaker with 1.0 % H3PO4, once with ethanol. After drying, mounting in Packard TopCount 96-well frame, and adding of 10 μL/well of Microscint, membranes are counted. IC50 values are calculated by linear regression analysis of the percentage inhibition of NVP-AEW541 in duplicate, at four concentrations (usually 0.01, 0.1, 1, and 10 μM). One unit of protein kinase activity is defined as 1 nmol of 33P transferred from [γ33P]ATP to the substrate protein per minute per mg of protein at 37 °C.
Cell Research:[1]
- Collapse
  • Cell lines: MCF-7 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 72 hours
  • Method: Between 3 × 103 and 6 × 103 cells/well are seeded in 96-well plates with a total media volume of 100 μL/well. Increasing concentrations of NVP-AEW541 is added 24 hours thereafter in quadruplicate. 72 hours later, cells are fixed by addition of 25 μL/well Glutaraldehyde (20%) and incubation for 10 min at RT. Cells are then washed 2× with 200 μL/well H2O and 100 μL Methylene Blue (0.05%) is added. After incubation for 10 min at RT, cells are washed 3× with 200 μL/well H2O. 200 μL/well HCl (3%) is added, and following incubation for 30 min at RT on a plate shaker, absorbance is measured at 650 nm.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female Harlan athymic nude mice weighing 18-25 g with NWT-21 cells
  • Dosages: 20, 30, or 50 mg/kg
  • Administration: Administered via p.o. twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 88 mg/mL (200.2 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 439.55
Formula

C27H29N5O

CAS No. 475489-16-8
Storage powder
in solvent
Synonyms AEW541
Smiles C1CN(C1)CC2CC(C2)N3C=C(C4=C(N=CN=C43)N)C5=CC(=CC=C5)OCC6=CC=CC=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy NVP-AEW541 | NVP-AEW541 supplier | purchase NVP-AEW541 | NVP-AEW541 cost | NVP-AEW541 manufacturer | order NVP-AEW541 | NVP-AEW541 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID